Research at the MHH
As a university hospital with the largest consultation hours for patients with Tourette syndrome in Germany, we not only endeavor to provide our patients with the best possible advice and treatment, but also to constantly gain new scientific insights into the causes and treatment of this disorder. However, this is only possible because people with Tourette syndrome agree to take part in scientific studies. We would like to take this opportunity to thank the large number of people who have actively supported us in our research into Tourette syndrome by participating in scientific studies over the past few years.
Below we present all the studies currently being conducted in our Clinical Department. You will also find detailed patient information for each study. If you are interested in participating in one of the studies listed below, we will be happy to answer any further questions you may have personally. Please get in touch with the relevant contact person directly.
It has long been known that tics occur more frequently in some families. To date, however, it has not been possible to identify a specific gene (= hereditary trait) that actually causes tics. The aim of this study is to discover the genes that are responsible for the inheritance of tics. Your participation will help to uncover the causes of Tourette's syndrome so that new treatment options can be developed in the long term.
Funding: Collaborative Genomic Studies of Tourette Disorder (TIC-Genetics): National Institute of Mental Health (NIMH): 1R01MH115958-01
Study participation: Only children can participate in this study together with their parents (so-called "parent-child trios"). The child must have Tourette syndrome or a tic disorder, but the parents must never have experienced tics. There is no age limit for participation, i.e. adult "children" of any age (including >18 years) can also take part, provided that both parents are willing to participate in the study. Please refer to the flyer for detailed information.
Contact if you wish to participate and for further questions: Phone +49 511 532 5524 or email: tourette-studien@mh-hannover.de (subject "TIC-Genetics").
We are looking for children and adolescents with Tourette's syndrome to investigate the efficacy and tolerability of a new drug for the treatment of tics
The investigational drug is called NOE-105 and is manufactured by the Swiss company Noema Pharma. In initial studies on humans, NOE-105 proved to be well tolerated. It is now to be tested in children and adolescents with Tourette's syndrome as part of a 16-week study. The purpose of the study is to determine the optimum dose for the new drug NOE-105. To this end, the dose will be gradually increased. The study is open and will take place without a control group, i.e. all participants will receive the drug NOE-105. Treatment with a "placebo" will not take place.
Contact if you wish to participate
Telephone: 0511-532-5524 / -5527 / -2494 or - 31741. Email: tourette-studien@mh-hannover.de.
Please call us or send us an email with the subject "NOEMA" if you are interested in participating in a study or would like further information.
The aim of this study is to investigate where the urge to perform a tic arises in the brain of people with Tourette syndrome and how the brain suppresses tics. In addition, we want to find out how the feeling of urge and the processing in the brain is changed by behavioral therapy using Habit Reversal Training (HRT). To answer these questions, we conduct behavioral therapy using HRT in people with Tourette syndrome. Before the start and after the end of therapy, the brain is also examined using MRI and EEG.
Contact if you wish to participate
☎ 0175 644 8771
Email: eberhard.antonia-leonie@mh-hannover.de or cramer.catharina@mh-hannover.de